The complexity and extended life cycles of existing animal models have hindered the study of Parkinson's disease during its preclinical stages. Now, a research team led by the Institut de ...

Previous studies in a rat model of Parkinson disease (PD) have shown that dyskinesia induced by L-DOPA—a treatment-limiting adverse effect of long-term administration—is caused by the release ...

U.S. Department of Defense awards $4 million to researchers at OHSU, University of Washington, VA Portland, VA Puget Sound to ...

Researchers from the Cleveland Clinic Genome Center have successfully applied advanced artificial intelligence (AI) genetics ...

Furthermore, in animal models, exposure to inhaled toxicants ... which have since been published in the Journal of Parkinson’s Disease, visit the link here. Approximately 1 million people ...

CBE is an irreversible GCase inhibitor, and its addition to a PFF can therefore serve as a model for GBA-1 Parkinson’s disease. Another animal model of PD is the rotenone model. The nGD model is ...

Rates of Parkinson’s disease are rising for reasons which ... What we see in our animal models is that we have a very fascinating molecule with all these effects that we're after, and now ...

Innovative treatment for Parkinson's disease: microscopic particles combined with light therapy offer a non-surgical solution ...

By contrast, in animal models of Parkinson's disease, nicotine alone has slight or no motor effects. However, nicotine may modulate dopamine transmission and has clear motor effects when ...

Ketamine disrupts abnormal brain activity, offering long-term relief for Parkinson’s dyskinesia in early clinical trials.